Publications by authors named "H Johnson-Ansah"
Article Synopsis
- Accelerated phase chronic myeloid leukemia (AP-CML) has a poorer prognosis than chronic phase (CP-CML), prompting researchers to test second-generation tyrosine kinase inhibitors (TKI2) as an initial treatment due to their reduced toxicity.
- In a study of 69 newly diagnosed patients with AP-CML, various health parameters were measured, revealing worse conditions in those with hematologic AP compared to cytogenetically defined AP.
- Regardless of the type of TKI2 treatment used, the patients achieved similar rates of clinical response and overall survival, suggesting that TKI2 can effectively manage AP-CML and mitigate the challenges associated with its advanced disease phase.
Article Synopsis
- - The study investigates the role of a specific oncofetal protein as a potential biomarker for chronic myeloid leukemia (CML), which is a cancer affecting blood-forming cells caused by genetic changes.
- - Researchers employed various techniques, including cell culture and ELISA, to demonstrate that this protein is overexpressed in CML patients and may be linked to the disease's progression and severity.
- - Findings indicate that the protein is upregulated in a kinase-dependent way and may significantly contribute to the mechanisms driving leukemogenesis in CML.
Article Synopsis
- - RNA splicing factors can play roles as both cancer-promoting proteins (oncoproteins) and tumor suppressors, and their alteration in cancer drives interest in targeting splicing mechanisms for treatment.
- - In a study on chronic myeloid leukemia (CML), researchers found that specific DNA methylation changes affected splicing in CML cells, indicating potential alterations in splicing proteins at diagnosis.
- - The investigation revealed a distinct splicing profile in CML cells compared to healthy cells and showed that combining traditional treatments with a spliceosome-targeted drug enhanced efficacy against CML without harming healthy cells, suggesting new treatment avenues.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Lydia Roy Jean-Claude Chomel Joëlle Guilhot Agnès Guerci-Bresler Martine Escoffre-Barbe Hyacinthe Johnson-Ansah
Br J Haematol
January 2023
Article Synopsis
- * A total of 79 patients participated, and the primary goal was to assess the cumulative molecular response rates over 12 months, with results showing significant rates of deep molecular response at 5 years.
- * While grade 3 neutropenia was common, it didn't lead to severe infections, and most patients continued the Peg-IFN treatment for a substantial time, resulting in notable molecular response rates after 12 and 24 months.
Article Synopsis
- * A total of 133 patients were assessed, and of the 86 who were identified as underdosed, those in the TDM group had higher imatinib levels and a significantly better major molecular response (MMR) at 12 months (67% for TDM vs. 39% for control).
- * TDM proved to be a feasible approach that not only heightened drug levels but also maintained a positive impact on treatment outcomes for up to three years.